PLD 105
Alternative Names: PLD-105Latest Information Update: 20 Oct 2022
At a glance
- Originator PeLeMed
- Class Antineoplastics
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 14 Oct 2022 Early research in Solid tumours in South Korea (unspecified route) (Pelemed pipeline, October 2022)